Altaris Acquires Meridian Medical Technologies from Pfizer

New York, NY—Altaris Capital Partners, LLC (collectively with its affiliates, “Altaris”) announced today that it completed the acquisition of Meridian Medical Technologies (“Meridian”), a global leader in emergency response and health security solutions with a focus on complex drug-device combination products, from Pfizer Inc. (NYSE:PFE).

Founded in 1958, Meridian is a pioneer in the field of emergency response auto-injectors. Meridian designs, develops, manufactures and supplies on-the-scene treatment solutions in partnership with a range of commercial customers and Government agencies. Meridian’s product portfolio includes critical medical countermeasures that are supplied to the United States Department of Defense, Emergency Medical Services and Homeland Security. Meridian has more than 750 employees and facilities in St. Louis, MO and Columbia, MD.

Milton Boyer has been appointed Chief Executive Officer of Meridian, with Tom Handel assuming the role of Chief Commercial Officer. Mr. Boyer is a seasoned industry executive with more than 25 years of experience in the development and manufacturing of pharmaceutical products, including previously serving as Chief Executive Officer of OsoBio, a sterile contract development and manufacturing organization that was a prior Altaris operating company.

Mr. Handel has more than 25 years of experience working at Meridian in various leadership positions. As Chief Commercial Officer, Mr. Handel will manage all commercial operations for Meridian, including corporate affairs, business development, global sales and marketing, and strategic client programs and alliance management.

Bass, Berry and Sims, PLC acted as legal counsel for Altaris, while Pfizer was advised by Wachtell, Lipton, Rosen & Katz.

Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Altaris’ operating companies are addressing some of the most complex problems in the healthcare industry, with the ultimate goal of improving access and outcomes for patients. Since inception in 2003, Altaris has invested in more than 45 healthcare companies that have contributed to advancements in the industry and generated significant value appreciation for investors. Altaris is headquartered in New York City and manages $6.0 billion of equity capital. For more information, please visit